Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 529Neoplasms 494Carcinoma, Non-Small-Cell Lung 404Prostatic Neoplasms 309Colorectal Neoplasms 293Lung Neoplasms 272Neoplasm Metastasis 225Leukemia, Myeloid, Acute 214Ovarian Neoplasms 197Pancreatic Neoplasms 188Multiple Myeloma 181Squamous Cell Carcinoma of Head and Neck 141Recurrence 139Stomach Neoplasms 137Brain Neoplasms 131Melanoma 129Carcinoma, Hepatocellular 128Endometrial Neoplasms 118Triple Negative Breast Neoplasms 116Glioblastoma 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 108Hematologic Neoplasms 99Head and Neck Neoplasms 99Urinary Bladder Neoplasms 97Carcinoma, Renal Cell 97Lymphoma 95Glioma 90Sarcoma 89Esophageal Neoplasms 87Lymphoma, Large B-Cell, Diffuse 84

Interventions

enzalutamide 3inavolisib 1abiraterone 1PF06821497 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-Resistant Prostate Cancer × 90 days × Clear all
NCT06629779 2026-05-20

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer

Phase 3 Recruiting
900 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04986423 2026-05-08

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics

Phase 2 Recruiting
200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT07287150 2026-05-06

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06318273 2026-04-08

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1 Recruiting
230 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡